Convatec Group (FRA:2CV) GF Value Rank: 10 (As of Jul. 17, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2CV Convatec Group PLC FRA:2CV
78 GF Score
Price €2.40
GF Value €3.01
! 4 Warning Signs
View Full Analysis

What is Convatec Group GF Value Rank?

Convatec Group FRA:2CV +1.69% 78 GF Value Rank is 10 as of Jul. 17, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates FRA:2CV with a GF Score™ of 78/100 and a GF Value™ of €3.01. The stock has 4 warning signs investors should review.

Convatec Group has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Convatec Group GF Value Rank Related Terms


FRA:2CV vs ISRG, BDX, MDLN: GF Value Rank Comparison

For the Medical Instruments & Supplies subindustry, Convatec Group's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Convatec Group GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Convatec Group's GF Value Rank falls into.


FRA:2CV
78GF Score
Convatec Group PLC FRA:2CV
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Convatec Group (FRA:2CV) has a GF Value Rank of 10 as of Jul. 17, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Convatec Group and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, Convatec Group's GF Value Rank has ranged from 3.00 to 10.00.
Is Convatec Group's GF Value Rank too high?
Convatec Group's current GF Value Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Convatec Group has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's GF Value Rank compare to ISRG and BDX?
Convatec Group's GF Value Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, Convatec Group's own GF Value Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Convatec Group and its competitors. Convatec Group's current GF Value Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Convatec Group (FRA:2CV) has a current GF Value Rank of 10. The stock's GF Value™ is €3.01, compared to a current price of €2.40 — trading 20.3% below its estimated fair value. The current GF Value Rank is 10, which is 67% above median its 10-year median of 6.00. Convatec Group's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Convatec Group (FRA:2CV), the current GF Value Rank is 10 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Convatec Group (FRA:2CV) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of €2.40 is trading 20.3% below its estimated GF Value™ of €3.01.

Key valuation signals for FRA:2CV:

  • GF Value Rank: 10 (67% above median its 10-year median of 6.00)
  • GF Value™: €3.01 vs. price of €2.40 (20.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the FRA:2CV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
78GF Score

Get the complete analysis for FRA:2CV

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price
€3.01
GF Value